| Primary |
| Intervertebral Disc Degeneration |
33.3% |
| Skull Fracture |
33.3% |
| Surgery |
33.3% |
|
| Incorrect Dose Administered |
50.0% |
| Product Formulation Issue |
50.0% |
|
| Secondary |
| Product Used For Unknown Indication |
33.5% |
| Arthralgia |
30.1% |
| Breakthrough Pain |
8.4% |
| Anxiety |
5.0% |
| Back Pain |
5.0% |
| Depression |
3.8% |
| Insomnia |
3.8% |
| Asthma |
1.7% |
| Neck Pain |
1.7% |
| Pain |
1.7% |
| Toothache |
1.7% |
| Drug Use For Unknown Indication |
0.8% |
| Antiinflammatory Therapy |
0.4% |
| Cystitis |
0.4% |
| Disturbance In Attention |
0.4% |
| Fibromyalgia |
0.4% |
| Inflammation |
0.4% |
| Pollakiuria |
0.4% |
| Upper Respiratory Tract Infection |
0.4% |
|
| Adrenal Insufficiency |
25.0% |
| Drug Dependence |
25.0% |
| Completed Suicide |
12.5% |
| Drug Screen Negative |
6.3% |
| Road Traffic Accident |
6.3% |
| Secondary Hypogonadism |
6.3% |
| Splenomegaly |
6.3% |
| Toxicity To Various Agents |
6.3% |
| Vomiting |
6.3% |
|
| Concomitant |
| Pain |
18.0% |
| Drug Use For Unknown Indication |
14.0% |
| Abdominal Pain |
7.9% |
| Nausea |
6.6% |
| Product Used For Unknown Indication |
6.1% |
| Rheumatoid Arthritis |
5.3% |
| Crohn's Disease |
5.0% |
| Contraception |
4.1% |
| Gastrooesophageal Reflux Disease |
3.9% |
| Constipation |
3.8% |
| Anxiety |
3.6% |
| Migraine |
3.0% |
| Depression |
2.9% |
| Anaemia |
2.7% |
| Muscle Relaxant Therapy |
2.7% |
| Hyperchlorhydria |
2.6% |
| Arthritis |
2.1% |
| Back Pain |
2.0% |
| Arthralgia |
1.9% |
| Decreased Appetite |
1.9% |
|
| Pulmonary Oedema |
13.2% |
| Vomiting |
7.7% |
| Nausea |
6.6% |
| Cholelithiasis |
5.5% |
| Fall |
5.5% |
| Malaise |
5.5% |
| Pulmonary Hypertension |
5.5% |
| Urinary Tract Infection |
5.5% |
| Urticaria |
5.5% |
| Death |
4.4% |
| Incorrect Dose Administered |
4.4% |
| Weight Decreased |
4.4% |
| Abdominal Pain |
3.3% |
| Abnormal Weight Gain |
3.3% |
| Anxiety |
3.3% |
| Cardiac Failure Congestive |
3.3% |
| Cholecystitis |
3.3% |
| Cholecystitis Chronic |
3.3% |
| Dyspnoea |
3.3% |
| Influenza |
3.3% |
|
